Needham raised the firm’s price target on AdTheorent to $3 from $2 and keeps a Buy rating on the shares after meeting with its CEO Jim Lawson at the 26th Annual Needham Growth Conference. The management’s top goals for 2024 include reporting strong and consistent revenue growth, expanding the Health product platform into new verticals, and continuing rapid adoption and growth of its Health product revenue, the analyst tells investors in a research note. AdTheorent should also benefit from Cookies deprecation because its tech stack uses predictive algorithms to score impressions before its DSP bids on them, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ADTH: